Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBT 032

Next Previous
X
Search
Drug Profile

BBT 032

Alternative Names: BBT-032; PegIFN-beta - Bolder BioTechnology; PegIFN-β - Bolder Biotechnology

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolder BioTechnology
  • Class Antidementias; Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon beta replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple sclerosis
  • Discontinued Cancer; COVID 2019 infections

Most Recent Events

  • 19 Jun 2023 BBT 032 is still in preclinical development for Multiple sclerosis (Parenteral) in US (Bolder Biotechnology pipeline, June 2023)
  • 29 Oct 2021 Discontinued - Preclinical for COVID-2019 infections in USA (Parenteral) (Bolder Biotechnology pipeline, October 2021)
  • 25 Aug 2020 Bolder Biotechnology announces intention to file an IND application to the US FDA for COVID-19 infections to initiate clinical trials

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top